Myeloma Center

Bibliography

Found 5 results
Author Title Type [ Year(Asc)]
Filters: Keyword is Clarithromycin  [Clear All Filters]
2014
Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D et al..  2014.  Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.. Leuk Lymphoma. 55(12):2842-9.
2010
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
2008
Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al..  2008.  Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al..  2008.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.
Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW et al..  2008.  Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.. Biol Blood Marrow Transplant. 14(7):795-8.